natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 14, wherein a total mass of the suspending particles exceeds a total mass of the active agent particles and a ratio of the total mass of the suspending particles to the total mass of the active agent particles is selected from up to 15, up to 17, up to 20, up to 30, up to 40, up to 50, up to 60, up to 75, up to 100, up to 150 and up to 200. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što je ukupna masa suspendirajućih čestica veća od ukupne mase čestica aktivnog sredstva, gdje se omjer ukupne mase suspendirajućih čestica i ukupne mase čestica aktivnog sredstva bira između do 15, do 17, do 20, do 30, do 40, do 50, do 60, do 75, do 100, do 150 i do 200.
The pharmaceutical composition according to claim 24, wherein the active agent is chemically stable over a period of at least 18 months when stored at 25°C. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 24, naznačen time što je aktivno sredstvo kemijski stabilno kroz period od najmanje 18 mjeseci prilikom skladištenja na 25 °C.
A pharmaceutical composition for use according to claim 25 wherein the disease or disorder is COPD. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 25, naznačen time što je bolest ili poremećaj COPD.
wherein at least one species of suspending particles comprises perforated microstructures wherein the perforated microstructures comprise DSPC (1,2-disteroyl-sn-glycero-3-phosphocholine) and calcium chloride. 
gdje najmanje jedna vrsta suspendirajućih čestice sadrže perforirane mikrostrukture, gdje perforirane mikrostrukture sadrže DSPC (1,2-disteroil-sn-glicero-3-fosfokolin) i kalcijev klorid.
The pharmaceutical composition according to claim 1, wherein the suspending particles remain co-located with the active agent particles even when subjected to buoyancy forces amplified by centrifugation at an acceleration selected from accelerations of at least 1 g, at least 10 g, at least 50 g, and at least 100 g. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što suspendirajuće čestice ostaju ko-locirane s čestica aktivnog sredstva čak i kada su podvrgnute uzgonskim silama uvećan centrifugiranjem uz ubrzanje koje se bira između ubrzanja od najmanje 1 g, najmanje 10 g, najmanje 50 g, te najmanje 100 g.
The pharmaceutical composition according to any preceding claim wherein the pharmaceutically acceptable salt of formoterol is selected from hydrochloric, hydrobromic, sulphuric, phosphoric acids, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se farmaceutski prihvatljiva sol formoterola bira između soli klorovodične, bromovodične, sumporne, fosforne, fumarne, maleinske, octene, mliječne, limunske, vinske, askorbinske, jantarne, glutarne, glukonske, trikarbalilne, oleinske, benzojeve, p-metoksibenzojeve, salicilne, o- i p-hidroksibenzojeve, p-klorbenzojeve, metansulfonske, p-toluensulfonske i 3-hidroksi-2-naftalenkarboksilne kiseline.
A pharmaceutical composition according to any one of claims 14-16, wherein the first species of active agent particles is suspended in the suspension medium at a concentration sufficient to provide a delivered dose of glycopyrrolate of up to 10 µg per actuation of the metered dose inhaler. 
Farmaceutski pripravak u skladu s bilo kojim od jedan od patentnih zahtjeva 14-16, naznačen time što je prva vrsta čestica aktivnog sredstva suspendirana u suspenzijskom mediju u koncentraciji dovoljnoj da osigura unesenu dozu glikopirolata od do 10 µg po aktuaciji inhalatora za odmjerene doze.
or alternatively R2 and R3, together with the nitrogen atom to which they are attached, constitute a group -C3-6-heterocycloalkyl chosen from: aziridine, azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or piperazine; the said heterocycloalkyl group being unsubstituted or substituted with a heteroaryl group, the said heteroaryl group being unsubstituted or substituted with a group - C1-4-fluoroalkyl; 
ili alternativno R2 i R3, zajedno s atomom dušika na koji su oni vezani, sačinjavaju skupinu -C3-6-heterocikloalkil koja se bira od: aziridina, azetidina, pirolidina, piperidina, morfolina, tiomorfolina ili piperazina; navedena heterocikloalkilna skupina je nesupstituirana ili supstituirana sa heteroarilnom skupinom, navedena heteroarilna skupina je nesupstituirana ili supstituirana sa skupinom -C1-4-fluoroalkil;
represents a heteroaryl group, which is unsubstituted or substituted with one or more groups R2'; 
predstavlja heteroarilnu skupinu, koja je nesupstituirana ili supstituirana s jednom ili više skupina R2';
represents a halogen atom, a group -C1-4-alkoxy, a formyl group (CHO) or a group -C1-4-alkyl, which is unsubstituted or substituted with a hydroxyl group; 
predstavlja halogeni atom, skupinu -C1-4-alkoksi, skupinu formil (CHO) ili skupinu -C1-4-alkil, koja je nesupstituirana ili supstituirana sa hidroksilnom skupinom;
represents a heteroaryl group, which is unsubstituted or substituted with a group -C1-3-alkyl; 
predstavlja heteroarilnu skupinu, koja je nesupstituirana ili supstituirana sa skupinom -C1-3-alkil;
represents an aryl group; 
predstavlja arilnu skupinu;
represents a hydrogen atom, an ethyl group, a 2,2,2-trifluoroethyl group or a methyl group, which is unsubstituted or substituted with a 1,2,3-triazole group substituted with a 3-(3-fluorophenyl)-2-oxo-1,3-oxazolidin-5-ylmethyl group; 
predstavlja vodikov atom, etilnu skupinu, skupinu 2,2,2-trifluoroetil ili skupinu metil, koja je nesupstituirana ili supstituirana sa skupinom 1,2,3-triazol supstituiranom sa skupinom 3-(3-fluorofenil)-2-okso-1,3-oksazolidin-5-ilmetil;
represents a quinolyl group, the said quinolyl group being unsubstituted or substituted with a chlorine atom; 
predstavlja skupinu kinolil, navedena kinolil skupina je nesupstituirana ili supstituirana s klorovim atomom;
represents a pyrazinyl group, the said pyrazinyl group being unsubstituted or substituted with one or more groups R2'; 
predstavlja pirazinil skupinu, navedena skupina pirazinil je nesupstituirana ili supstituirana s jednom ili više skupina R2';
represents a 1,8-naphthyridinyl group substituted with a methyl group; 
predstavlja skupinu 1,8-naftiridinil supstituiranu sa skupinom metil;
b-2) the compound of formula (VI) thus obtained is reacted with a compound of formula (VII): 
[image] b-2) tako dobiveni spoj s formulom (VI) reagira sa spojem s formulom (VII):
The antibody or antigen-binding fragment for use as in claim 12, wherein the B cell-related disorder is 
Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 12, gdje je poremećaj povezan s B-stanicama
The antibody or antigen-binding fragment for use as in claim 13, wherein the autoimmune disease is systemic lupus erythematosus or rheumatoid arthritis. 
Protutijelo ili antigen-vezujući fragment za uporabu kao u patentnom zahtjevu 13, gdje je autoimuna bolest sustavni eritematozni lupus ili reumatoidni artritis.
The solar collector according to claim 1, wherein the content of the coloring agent in the binder composition is in the range of 0.1 to 10 wt.-% with respect to the total weight of the binder composition. 
Solarni kolektor sukladno zahtjevu 1, pri čemu sadržaj sredstva za bojanje u spoju za povezivanje iznosi između 0.1 do 10 tež.-% u odnosu na ukupnu težinu spoja za povezivanje.
Use of mineral wool insulation comprising mineral wool fibres in a solar collector, characterized in that the mineral wool insulation comprises a binder composition which comprises a binder and a coloring agent to provide effective insulation whilst avoiding the use of a film or foil laminated using an adhesive as a top layer of said mineral wool insulation. 
Uporaba izolacije mineralne vune obuhvaća vlakna mineralne vune u solarnom kolektoru, naznačena time što izolacija mineralne vune obuhvaća spoj za povezivanje koji obuhvaća sredstvo za povezivanje i sredstvo za bojanje izbjegavajući uporabu filma ili folije laminirane uporabom ljepila kao gornjeg sloja navedene izolacije mineralne vune.
Use of a calibrator material comprising mammalian bodily fluid to calibrate an immunoassay for detection of autoantibodies, wherein said calibrator material comprises a drainage fluid, exudate or transudate. 
Uporaba materijala kalibratora koji sadrži tjelesnu tekućinu sisavca za kalibriranje imunoispitivanja za detekciju autoprotutijela, pri čemu navedeni materijal kalibratora sadrži drenažnu tekućinu, eksudat ili transudat.
Use according to claim 2 wherein the calibration material comprises 
Uporaba u skladu s patentnim zahtjevom 2 pri čemu kalibracijski materijal sadrži
detection of autoantibodies to cancer, or 
detekciju autoprotutijela na rak, ili
for detection of autoantibodies to early neoplastic change. 
detekciju autoprotutijela na ranu neoplastičnu promjenu.
A method of calibrating an immunoassay for detection of autoantibodies which comprises: 
Metoda za kalibriranje imunoispitivanja za detekciju autoprotutijela koja obuhvaća:
contacting each of a plurality of different dilutions of a calibration material comprising a mammalian bodily fluid with an antigen specific for an autoantibody, wherein said mammalian bodily fluid is known to contain autoantibodies immunologically specific for the antigen and wherein said calibrator material comprises a drainage fluid, exudate or transudate; 
doticaj svake množine različitih razrjeđenja kalibracijskog materijala koje sadrži tjelesnu tekućinu sisavca s antigenom specifičnim za autoprotutijelo, pri čemu je poznato da navedena tjelesna tekućina sisavca sadrži autoprotutijela imunološki specifična za antigen i pri čemu navedeni materijal kalibratora sadrži drenažnu tekućinu, eksudat ili transudat;
detecting the amount of specific binding between said antigen and autoantibody present in the calibration material; and 
detektiranje količine specifičnog vezanja između navedenog antigena i autoprotutijela prisutnog u kalibracijskom materijalu; i
plotting or calculating a curve of the amount of said specific binding versus the dilution of the calibration material for each dilution of calibration material used in step (a), thereby calibrating an immunoassay using said antigen for detection of said autoantibody. 
crtanje ili računanje krivulje količine navedenog specifičnog vezanja naspram razrjeđenja kalibracijskog materijala za svako razrjeđenje kalibracijskog materijala korištenog u koraku (a), stoga kalibriranje imunoispitivanja koristeći navedeni antigen za detekciju navedenog autoprotutijela.
The method of claim 5 wherein the calibration material comprises human bodily fluid, comprises bodily fluid collected from one or more subjects with cancer, or 
Metoda iz patentnog zahtjeva 5 pri čemu kalibracijski materijal sadrži ljudsku tjelesnu tekućinu, sadrži tjelesnu tekućinu sakupljenu od jednog ili više subjekta s rakom, ili
The method of claim 6 wherein the calibration material comprises 
Metoda iz patentnog zahtjeva 6 pri čemu kalibracijski materijal sadrži
The method of any one of claims 5 to 8 wherein the antigen of part (a) is used at a concentration 
Metoda iz bilo kojeg od patentnih zahtjeva 5 do 8 pri čemu se antigen ili dio (a) koristi kod koncentracije
An immunoassay kit for detection of autoantibodies, said kit comprising a set of calibration standards for use in calibrating an immunoassay for detection of autoantibodies, wherein each calibration standard in said set comprises a different dilution of a mammalian bodily fluid, said mammalian bodily fluid being known to contain native human autoantibodies, and wherein the mammalian bodily fluid is a drainage fluid, exudate or transudate and an immunoassay reagent comprising an antigen immunologically specific for said autoantibodies. 
Komplet za imunoispitivanje za detekciju autoprotutijela, navedeni komplet sadrži niz kalibracijskih standarda za uporabu u kalibriranju imunoispitivanja za detekciju autoprotutijela, pri čemu svaki kalibracijski standard u navedenom nizu sadrži različito razrjeđenje tjelesne tekućine sisavca, za navedenu tjelesnu tekućinu sisavca je poznato da sadrži nativna ljudska autoprotutijela, i pri čemu je tjelesna tekućina sisavca drenažna tekućina, eksudat ili transudat i reagens za imunoispitivanje sadrži antigen imunološki specifičan za navedena autoprotutijela.
The pharmaceutical composition according to claim 14, wherein a ratio of the total mass of the at least one species of suspending particles to the total mass of at least one species of agent particles is selected from above 1 and up to 1.5, up to 5, up to 10, up to 15, up to 17, up to 20, up to 30, up to 40, up to 50, up to 60, up to 75, up to 100, up to 150, and up to 200. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što je ukupna masa suspendirajućih čestica veća od ukupne mase čestica aktivnog sredstva, gdje se omjer ukupne mase suspendirajućih čestica i ukupne mase čestica aktivnog sredstva bira između do 15, do 17, do 20, do 30, do 40, do 50, do 60, do 75, do 100, do 150 i do 200.
A pharmaceutical composition comprising the preparation of claim 1 . A method of treating cholestatic liver disease, non-alcoholic steato-hepatitis, alcoholic steato-hepatitis and/or arteriosclerosis by administering to a subject a pharmaceutical composition comprising a chemically pure, single-polymorphic, crystalline preparation of Nor-UDCA or of a pharmaceutically acceptable salt thereof containing a total amount of chemical impurities less than 2%, and at least 60% of the polymorph particles have a size <10 μm. The method of claim 7, wherein the cholestatic liver disease is selected from the group consisting of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što raspodjela veličina čestica u farmaceutskom pripravku uključuje najmanje 60% čestice s veličinom < 10 µm. Polimorf u skladu s bilo kojim od patentnih zahtjeva 1 do 5, ili farmaceutski pripravak u skladu s patentnim zahtjevom 6 ili 7, naznačeni time što su namijenjeni upotrebi u liječenju kolestatske bolesti jetre, gdje se kolestatsku bolest jetre po mogućnosti bira iz skupine koju čine primarna bilijarna ciroza (PBC), primarni sklerozirajući kolangitis (PSC), autoimuni hepatitis (AIH) i preklapajući sindromi, uključujući sindrome koji se preklapaju s AIH.
crystallizing the potassium salt of Nor-UDCA; and dissolving the potassium salt in a solvent and acidifying the solution to obtain pure Nor-UDCA. 
– kristaliziranja kalijeve soli Nor-UDCA; i – izbornog otapanja kalijeve soli u otapalu, te zakiseljavanje otopine kako bi se dobio čisti Nor-UDCA.
converting the compound of formula (C) into a compound of formula (D) in crude form 
prevođenja spoja formule (C) u spoj formule (D) u sirovom obliku [image];
treating the compound of formula (D) in crude form with KOH under conditions to crystallize the potassium salt of Nor-UDCA; 
i obrade spoja formule (D) u sirovom obliku s KOH u uvjetima za kristaliziranje kalijeve soli Nor-UDCA;
represents a group of formula: 
predstavlja grupu formule:
A compound according to any one of claims 1 to 28 for use in the treatment of a pathological condition or disease associated with β2 adrenergic receptor agonist and muscarinic receptor antagonist activities, which condition or disease is preferably selected from pulmonary diseases, pre-labor, glaucoma, neurological disorders, cardiac disorders, inflammation and gastrointestinal disorders, and is more preferably asthma and or chronic obstructive pulmonary disease. 
Spoj prema bilo kojem zahtjevu od 1 do 11 za primjenu u liječenju patološkog stanja ili bolesti povezane s djelovanjem agonista β2 adrenergičkog receptora i antagonista muskarinskog acetilkolinskog receptora M3, pri čemu je stanje ili bolest poželjno odabrano iz plućnih bolesti, prijevremenog poroda, glaukoma, neuroloških poremećaja, srčanih poremećaja, upalnih ili gastrointestinalnih poremećaja, a poželjnije je astma ili kronična opstruktivna plućna bolest.
The pharmaceutical composition of claim 3 or 4, wherein the pharmaceutical composition is used for a cancer or an infectious disease. 
Farmaceutski sastav prema zahtjevu 3, naznačen time, da se upotrebljava u liječenju raka ili infektivne bolesti.
The pharmaceutical composition of any one of claims 3 to 6, comprising proteins in an amount of from 0.1 mg/kg to 0.4 mg/kg for one dose. 
Farmaceutski sastav za uporabu prema bilo kojem od zahtjeva 2 do 6, naznačen time, da obuhvaća proteine u količini od 0,2 mg/kg do 2,0 mg/kg za jednu dozu.
Redundant overvoltage circuit breaker with a rotational disk and with an added electronic assembly intended to extend a life span of an overvoltage component according to claim 1, characterised in that a threshold of overload above a declared value is precisely set by dimensioning the volume of the varistor, metallic varistor connecting electrodes, and the selection of the point of melting of the soldering flux of the thermal circuit breaker; that a selection of material for the body of the varistor and the varistor electrodes additionally contributes to a precise setting of the threshold of safe shutoff of the varistor. 
Redundantni strujni prekidač prekomjernog napona s rotacijskim diskom i s dodanim elektroničkim sklopom za produljenje životnog vijeka komponente s prekomjernim naponom, prema zahtjevu 1, naznačen time, da je precizno postavljen prag prekomjernog napona iznad prijavljene vrijednosti, pomoću dimenzioniranja volumena varistora i metalnih elektroda spojenih na varistor te odabiranjem točke taljenja tekućeg sredstva za zavarivanje od toplinskog strujnog prekidača; pri čemu odabiranje materijala za tijelo varistora i za elektrode varistora, dodatno pridonosi preciznom postavljanju praga za sigurno isključivanje varistora.
Mill (20) according to Claim 12 or 13, wherein opening of the hatch (42) is automatically controlled depending on the temperature in the rotating mass of waste R . 
Mlin (20) sukladno zahtjevu 12 ili 13, pri čemu je otvor (42) automatski kontroliran ovisno o temperaturi rotirajuće mase otpada R.
Mill (20) according to claim 3, wherein automatic opening of the hatch (42) occurs when a threshold temperature is reached or when a threshold gradient in the temperature increase is recorded. 
Mlin (20) sukladno zahtjevu 3, pri čemu se automatsko otvaranje otvora (42) događa kada je postignut prag temperature ili kada je zabilježeno povećanje gradijenta temperaturnog praga.
Het denotes a divalent monocyclic or fused bicyclic unsaturated, saturated or aromatic heterocyclic group having 1 to 5 heteroatom independently selected from N, O, S and/or a group -C=O, which may be further substituted with 1 to 4 substituent selected from Hal, C1-C6-alkyl, -(CH2)mOC1-C6-alkyl, CN, OH, NO2 CF3,-(CH2)mCOOH, -(CH2)mCOOC1-C6-alkyl; 
Het označava dvovalentnu monocikličku ili kondenziranu bicikličku nezasićenu, zasićenu ili aromatsku heterocikličku skupinu koja ima 1 do 5 heteroatoma koji se neovisno biraju od N, O, S i/ili od skupine -C=O, koja može biti dalje supstituirana s 1 do 4 supstituenata koji se biraju od Hal, C1-C6-alkil, -(CH2)mOC1-C6-alkil, CN, OH, NO2 CF3,-(CH2)mCOOH, -(CH2)mCOOC1-C6-alkil;
A compound of Formula (I) according to claims 1 to 3 wherein the compound is selected from the following group: Ex 
Spoj s formulom (I) prema zahtjevima 1 do 3 naznačen time da je spoj izabran iz sljedeće skupine:
A compound according to claim 5 for use in the treatment or prevention of inflammatory disease, autoimmune disorder, cancer or multiple sclerosis and related disorders. 
Spoj prema zahtjevu 5, naznačen time da je za uporabu za liječenje ili sprječavanje upalne bolesti, autoimunog poremećaja, raka ili mraultiple skleroze i srodnih poremećaja.
A compound of claim 6 wherein the disease is selected from Rheumatoid Arthritis Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Cronh's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, Cancer. 
Spoj prema zahtjevu 6, naznačen time da se bolest bira iz skupa koji čine reumatoidni artritis, psorijatični artritis, osteoartritis, sistemski eritematozni lupus, lupus nefritis, ankilozni spondilitis, osteoporoza, sistemska skleroza, multipla skleroza, psorijaza, dijabetes tipa I, dijabetes tipa II, upalna bolest crijeva (Cronhova bolest i ulcerozni kolitis), hiperimunoglobulinemija D i sindrom periodičke groznice, periodični sindromi vezani za kriopirin, Schnitzlerov sindrom, sistemski juvenilni idiopatski artritis, Stillova bolest odrasle dobi, giht, pseudogout, SAPHO sindrom, Castlemanova bolest, sepsa, udar, ateroskleroza, celijakija, DIRA (nedostatak antagonista IL-1 receptora) Alzheimerova bolest, Parkinsonova bolest, rak.
an effective amount of a compound of formula (I) according to claim 1, and 
učinkovite količine spoja s formulom (I) prema zahtjevu 1, te
A pharmaceutical composition according to claim 12 which additionnally contains at least one further immunomodulating agents. 
Farmaceutski pripravak prema zahtjevu 12, naznačen time da dodatno sadrži barem jedno dodatno imunomodulacijsko sredstvo.
Interferon-β (IFN-β) for use in the treatment of lower respiratory tract illness that has developed during or following an established influenza like illness (ILI), wherein said treatment is by aerosol delivery of said medicament to the lower respiratory tract; wherein ILI is defined as (a) a fever >37.8°C plus two of the following symptoms: headache, cough, sore throat and myalgia and (b) confirmed influenza; wherein established ILI means an illness in which the symptoms have been apparent for at least 48 hours; wherein the lower respiratory tract illness is caused by influenza; and wherein the IFN-β is delivered to the lower respiratory tract by aerosol at least 48 hours after ILI symptoms become apparent. 
Interferon-β (IFN-β) za liječenje bolesti donjeg dišnog sustava koja se razvila tijekom ili nakon dijagnosticiranja bolesti gripe (ILI), pri čemu je navedeni tretman pomoću aerosol apliciranja navedenog lijeka do donjeg dišnog sustava; pri čemu je ILI definiran kao (a) groznica >37,8°C plus dva od slijedećih simptoma: glavobolja, kašalj, upala grla i mijalgija i/ili (b) potvrđena gripa; pri čemu dijagnosticirani ILI označava bolest u kojoj su simptomi postali očiti tijekom najmanje 48 sati; pri čemu je bolest donjeg dišnog sustava uzrokovana gripom; i pri čemu je IFN-β apliciran do donjeg dišnog sustava pomoću aerosola za najmanje 48 sati nakon što su simptomi ILI postali očiti.
enhanced antibody dependent cell mediated cytotoxicity (ADCC); 
poboljšanu staničnu citotoksičnost ovisnu o protutijelima (ADCC);
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim lor 2 in combination with a pharmaceutically acceptable excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema zahtjevu 1 ili 2, u kombinaciji s farmaceutski prihvatljivim pomoćnim sredstvom.